ClinicalTrials.gg
Not yet recruitingNCT06570785IOPSUpdated Nov 20, 2024

IOPS Technology During Cannnulation of Contralateral Limb in EVAR

An observational study in Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm Without Rupture and Radiation Exposure, sponsored by Clinical Centre of Serbia. Not yet recruiting at 1 site in Serbia. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Clinical Centre of Serbia · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
40 Years to 100 Years
Sex
All
01

Study summary

Short-term results are favorable for EndoVascular Aneurysm Repair (EVAR) compared to open surgery. One of the major drawbacks to this shift is the need for fluoroscopy and contrast dyes to visualise endovascular devices. The use of fluoroscopy exposes both patients and caregivers to harmful ionizing radiation. Because of the harmful effects of radiation, recent radiation protection guidelines strongly recommend as low as reasonably achievable (ALARA) principle. The need for additional radiation-reducing navigation techniques is high, with the ultimate goal of performing endovascular procedures without radiation at all.

In response to these challenges, Centerline Biomedical (Cleveland, Ohio, USA) has developed a proprietary electromagnetic tracking and positioning system called the Intra-Operative Positioning System (IOPS). This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the radiation exposure for patients and healthcare professionals. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.

This study aims to describe the influence of IOPS technology on radiation exposure during cannulation of the contralateral limb (CL) during standard EVAR.

Read the detailed description

Background:

The current standard of care for abdominal aortic aneurysm (AAA) is endovascular aneurysm repair (EVAR) which has been suggested as the treatment of choice by both European and American guidelines . Although short-term results are favorable for EVAR compared to open surgery, one of the major drawbacks to this shift is the need for fluoroscopy and contrast dyes to visualise endovascular devices. The contrast dyes used during these procedures can induce renal failure in patients with preexisting renal dysfunction. Meanwhile, the use of fluoroscopy exposes both patients and caregivers to harmful ionizing radiation. Because of the harmful effects of radiation, recent radiation protection guidelines strongly recommend as low as reasonably achievable (ALARA) principle.

In response to these challenges, Centerline Biomedical (Cleveland, Ohio, USA) has developed a proprietary electromagnetic tracking and positioning system called the Intra-Operative Positioning System (IOPS). This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. Image guidance is provided using 3D maps of the vasculature, generated from thin-slice contrast-enhanced preoperative computerised tomography angiography (CTA). At the start of the procedure, a self-adhesive sterile fiducial tracking pad is attached to the patient's lumbar region, and the angiography system is used to perform a non-contrast-enhanced cone-beam CT scan. The cone beam CT volume is then loaded onto the IOPS cart and manually aligned with the preoperative CT volume. This work can be performed in parallel with achieving vascular access, with minimal effects on the procedure time. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed. This technology has been used by other centres for visceral and renal cannulation during complex aortic aneurysm procedures.

Previously there have been publications on the use of Fiber Optic Real Shape (FORS) Technology with both complex and standard endovascular aneurysm repair (EVAR) showing the potential benefit of this technology in procedural time and radiation reduction. However, the need for additional radiation-reducing navigation techniques is high, with the ultimate goal of performing endovascular procedures without radiation at all.

This study aims to describe the influence of IOPS technology on radiation exposure during cannulation of the contralateral limb (CL) during standard EVAR.

Study outcome and sample size:

Technical success of using IOPS technology during cannulation of CL Navigation time expressed through total procedural time, CL cannulation time, fluoroscopy time (overall and during CL cannulation) Radiation exposure parameters that were described in the latest European Society for Vascular Surgery (ESVS) radiation guidelines: cumulative air kerma (CAK), kerma area product (KAP), fluoroscopy time (FT) (4) To ensure sufficient statistical power to answer hypothetical questions, 80 subjects will be entered into the database. Navigation time and radiation exposure parameters are used to calculate the sample size. Assuming the difference in terms of both parameters, 30 patients are required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (conventional and IOPS group), assuming a 20% rate of missing data, a total N of 80 patients is required.

Research Design:

This prospective study includes patients with standard AAA undergoing EVAR within instructions for use (IFU) treated from September 1st, 2024 until May 1st, 2025 at the Clinic for Vascular and Endovascular Surgery, University Clinical Centre of Serbia.

Procedures Involved:

This study will not impact the care that patients receive. Patient data will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, comorbidities, diagnostic imaging information (describing the morphology of the aortoiliac segment), and periprocedural information related to the timing and radiation.

Data management:

After the data has been collected at a participating institution, the data will be transmitted to an online database which will be available only to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/University Clinical Center of Serbia/Medical Faculty, University of Belgrade.

Risks to Subjects:

As this is a prospective observational study performing EVAR in standard AAA using new radiation protection technology for visualisation of wires and catheters in a newly equipped angio suite, there are minimal potential physical risks to subjects. There is also a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information.

Potential Benefits to Subjects:

There is a potential benefit to the subjects involved in the IOPS group. Hypothetically they will have lower procedural times and lower radiation doses during CL cannulation. Future patients treated with this technology might have reduced radiation and cannulation times. This will make it possible to perform more and more procedures with a minimal amount of radiation, or even without radiation at all.

Statistics and Data Analysis:

Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and will be compared using the chi-square test or Fisher exact test. Differences will be considered statistically significant at p \< 0.05. Analyses will be performed using SPSS software, version 28.0 (SPSS, Chicago, ILLINOIS, USA).

Conflict of Interest:

Since this is a physician-initiated trial, the investigators have no conflict of interest to report.

Funding Source:

There are no plans to apply for additional grants or additional funding. No funding is required for the completion of this study.

Publication Plan:

All research personnel included in this project will be eligible for authorship in any resulting abstracts and publications following the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.

02

Conditions studied

  • Abdominal Aortic Aneurysm
  • Abdominal Aortic Aneurysm Without Rupture
  • Radiation Exposure

Keywords

  • Abdominal Aortic Aneurysm
  • EndoVascular Aneurysm Repair
  • Radiation Protection
03

In context

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

This study's planned enrollment of 80 is below the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.

Browse Aortic Aneurysm, Abdominal studies →

Lead sponsor

Clinical Centre of Serbia is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with infrarenal AAA undergoing standard EVAR according to the IFUs of the manufacturer will be stratified into two groups:

  1. IOPS group (used during CL cannulation)
  2. Conventional group (as usual using a standardised approach for EVAR)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients (over 18 years of age) with infrarenal AAA treated between 1st September 2024 and 1st May 2025 undergoing standard EVAR according to the IFU

Exclusion criteria

Exclusion Criteria:

  • Patients who are pregnant
  • Patients who are under 40 years of age
  • Patients who have symptomatic or ruptured AAA
  • Patients with more advanced AAA: juxtarenal, pararenal, suprarenal, thoracic, thoracoabdominal AAA
  • Non-atherosclerotic origin of disease: dissection, connective tissue disorders, mycotic AAA, posttraumatic AAA
  • Patients who were treated in a conservative manner
  • Patients undergoing open surgery
  • Patients undergoing more advanced treatment options: fenestrated/branched EVAR, endostaplers, chimney EVAR, iliac branch devices, etc.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • IOPS group

    Patients with AAA undergoing standard EVAR according to the IFU using IOPS technology for visulisation of guidewires and catheter for the cannulation of contralateral limb.

    Device: Intra-Operative Positioning System (IOPS)

  • Conventional group

    Patients with AAA undergoing standard EVAR according to the IFU using standardised approach and materials.

    Device: Conventional group

Interventions

  • DeviceIntra-Operative Positioning System (IOPS)

    This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.

  • DeviceConventional group

    This group will be treated using standardised materials (wires, catheters) during EVAR.

06

What researchers measure

Primary outcomes

  1. Fluoroscopic time per participant required for cannulation

    Record cumulative fluoroscopy time reported by fluoroscopic system before and after cannulation of contralateral limb

    Time frame: Cannulation of contralateral limb during the intervention

  2. Number of participants with technical success of gate catheterisation

    Definition of technical success with fluoroscopy: Cannulation completed retrograde; Definition of technical success with IOPS: Cannulation completed retrograde using IOPS catheter

    Time frame: Cannulation of contralateral limb during the intervention

Secondary outcomes

  1. Clock time per participant required for cannulation

    Use stopwatch, or record clock time before and after cannulation of contralateral limb

    Time frame: Cannulation of contralateral limb during the intervention

  2. Radiation dose per participant during cannulation

    Cumulative air kerma \[CAK\], air kerma area product \[KAP\], excluding digital subtraction angiography time

    Time frame: Record radiation reported by fluoro system before and after cannulation of contralateral limb during the intervention

07

Study locations

1 site
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
08

References and documents

Publications

  • Wanhainen A, Van Herzeele I, Bastos Goncalves F, Bellmunt Montoya S, Berard X, Boyle JR, D'Oria M, Prendes CF, Karkos CD, Kazimierczak A, Koelemay MJW, Kolbel T, Mani K, Melissano G, Powell JT, Trimarchi S, Tsilimparis N; ESVS Guidelines Committee; Antoniou GA, Bjorck M, Coscas R, Dias NV, Kolh P, Lepidi S, Mees BME, Resch TA, Ricco JB, Tulamo R, Twine CP; Document Reviewers; Branzan D, Cheng SWK, Dalman RL, Dick F, Golledge J, Haulon S, van Herwaarden JA, Ilic NS, Jawien A, Mastracci TM, Oderich GS, Verzini F, Yeung KK. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024 Feb;67(2):192-331. doi: 10.1016/j.ejvs.2023.11.002. Epub 2024 Jan 23. PubMed 38307694 ↗
  • Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, Mastracci TM, Mell M, Murad MH, Nguyen LL, Oderich GS, Patel MS, Schermerhorn ML, Starnes BW. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018 Jan;67(1):2-77.e2. doi: 10.1016/j.jvs.2017.10.044. PubMed 29268916 ↗
  • Antoniou GA, Antoniou SA, Torella F. Editor's Choice - Endovascular vs. Open Repair for Abdominal Aortic Aneurysm: Systematic Review and Meta-analysis of Updated Peri-operative and Long Term Data of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2020 Mar;59(3):385-397. doi: 10.1016/j.ejvs.2019.11.030. Epub 2019 Dec 30. PubMed 31899100 ↗
  • Zlatanovic P, Davidovic L, Mascia D, Ancetti S, Yeung KK, Jongkind V, Viitala H, Venermo M, Wiersema A, Chiesa R, Gargiulo M. Acute kidney injury in patients undergoing endovascular or open repair of juxtarenal or pararenal aortic aneurysms. J Vasc Surg. 2024 Jun;79(6):1347-1359.e3. doi: 10.1016/j.jvs.2024.02.021. Epub 2024 Feb 22. PubMed 38395093 ↗
  • Modarai B, Haulon S, Ainsbury E, Bockler D, Vano-Carruana E, Dawson J, Farber M, Van Herzeele I, Hertault A, van Herwaarden J, Patel A, Wanhainen A, Weiss S, Esvs Guidelines Committee, Bastos Goncalves F, Bjorck M, Chakfe N, de Borst GJ, Coscas R, Dias NV, Dick F, Hinchliffe RJ, Kakkos SK, Koncar IB, Kolh P, Lindholt JS, Trimarchi S, Tulamo R, Twine CP, Vermassen F, Document Reviewers, Bacher K, Brountzos E, Fanelli F, Fidalgo Domingos LA, Gargiulo M, Mani K, Mastracci TM, Maurel B, Morgan RA, Schneider P. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Radiation Safety. Eur J Vasc Endovasc Surg. 2023 Feb;65(2):171-222. doi: 10.1016/j.ejvs.2022.09.005. Epub 2022 Sep 18. No abstract available. PubMed 36130680 ↗
  • Finnesgard EJ, Simons JP, Jones DW, Judelson DR, Aiello FA, Boitano LT, Sorensen CM, Nguyen TT, Schanzer A. Initial single-center experience using Fiber Optic RealShape guidance in complex endovascular aortic repair. J Vasc Surg. 2023 Apr;77(4):975-981. doi: 10.1016/j.jvs.2022.11.041. Epub 2022 Nov 13. PubMed 36384183 ↗
  • Klaassen J, Hazenberg CEVB, Bloemert-Tuin T, Wulms SCA, Teraa M, van Herwaarden JA. Editor's Choice - Radiation Dose Reduction During Contralateral Limb Cannulation Using Fiber Optic RealShape Technology in Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2024 Apr;67(4):594-600. doi: 10.1016/j.ejvs.2023.10.041. Epub 2023 Nov 3. PubMed 37925100 ↗
  • Muluk SC, Elrakhawy M, Chess B, Rosales C, Goel V. Successful endovascular treatment of severe chronic mesenteric ischemia facilitated by intraoperative positioning system image guidance. J Vasc Surg Cases Innov Tech. 2021 Nov 22;8(1):60-65. doi: 10.1016/j.jvscit.2021.11.001. eCollection 2022 Mar. PubMed 35118217 ↗

Individual participant data

Plan to share: Undecided — This will be decided among the study group, once study has been completed.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Sep 2025, 7 months later.

Of 67 non-industry observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 7 months is below that.

Counting every sponsor, half of 91 studies reached it within 48 months; a quarter within 24 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 26, 2024
StartEst.
Jan 20, 2025
Primary completionEst.
Sep 8, 2025
CompletionEst.
Nov 3, 2025
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570785
Lead sponsor
Clinical Centre of Serbia
Collaborators
Centerline Biomedical, Inc.
Responsible party
Petar Zlatanovic (Principal Investigator MD PhD FEBVS, Clinical Centre of Serbia) — Principal investigator
First posted
Aug 26, 2024
Start date
Jan 20, 2025 (estimated)
Primary completion
Sep 8, 2025 (estimated)
Completion
Nov 3, 2025 (estimated)
Last update
Nov 20, 2024

Study contacts

Petar Zlatanovic, MD PhD FEBVS
Contact
petar91goldy@gmail.com
+381668300278
Igor Koncar, MD PhD
Contact
dr.koncar@gmail.com
+381668300290
Igor Koncar, MD PhD
study chair · University Clinical Centre of Serbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion